{"id":961028,"date":"2026-05-11T18:25:58","date_gmt":"2026-05-11T22:25:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-reports-first-quarter-2026-financial-results\/"},"modified":"2026-05-11T18:25:58","modified_gmt":"2026-05-11T22:25:58","slug":"catalyst-pharmaceuticals-reports-first-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-reports-first-quarter-2026-financial-results\/","title":{"rendered":"Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results"},"content":{"rendered":"
\n

\n Delivered Q1 2026 Total Revenues\u00a0<\/em>
\n of\u00a0$149.4 Million<\/em>
\n
\n Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE\u00ae & AGAMREE\u00ae <\/em>
\n
\n Reported Cash and Cash Equivalents of <\/em>
\n $755.9 <\/em>
\n Million and No Funded Debt as of March 31, 2026<\/em>\n <\/p>\n

CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc.\u00a0(“Catalyst” or “Company”) (Nasdaq: CPRX), today reported financial results for the first quarter of 2026 and provided a business update.<\/p>\n

\n Financial Highlights<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n For the Three Months Ended March 31, <\/strong>\n <\/td>\n\n 2026<\/strong>
\n \n <\/td>\n		\n 2025<\/strong>
\n \n <\/td>\n		\n % Change<\/strong>\n <\/td>\n<\/tr>\n
(In thousands, except per share data)<\/em><\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Product Revenue, net<\/td>\n$<\/td>\n149,343<\/td>\n$<\/td>\n141,400<\/td>\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0 5.6<\/td>\n%<\/td>\n<\/tr>\n
FIRDAPSE Product Revenue, net<\/td>\n$<\/td>\n98,859<\/td>\n$<\/td>\n83,731<\/td>\n\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 18.1<\/td>\n%<\/td>\n<\/tr>\n
AGAMREE Product Revenue, net<\/td>\n$<\/td>\n36,713<\/td>\n$<\/td>\n22,042<\/td>\n66.6<\/td>\n%<\/td>\n<\/tr>\n
FYCOMPA Product Revenue, net<\/td>\n$<\/td>\n13,771<\/td>\n$<\/td>\n35,627<\/td>\n(61.3<\/td>\n%)<\/td>\n<\/tr>\n
GAAP Net Income<\/td>\n$<\/td>\n63,734<\/td>\n$<\/td>\n56,737<\/td>\n12.3<\/td>\n%<\/td>\n<\/tr>\n
Non-GAAP Net Income *<\/td>\n$<\/td>\n100,262<\/td>\n$<\/td>\n86,596<\/td>\n15.8<\/td>\n%<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
GAAP Net Income Per Share – Basic<\/td>\n$<\/td>\n0.52<\/td>\n$<\/td>\n0.47<\/td>\n10.6<\/td>\n%<\/td>\n<\/tr>\n
Non-GAAP Net Income Per Share \u2013 Basic*<\/td>\n$<\/td>\n0.82<\/td>\n$<\/td>\n0.71<\/td>\n15.5<\/td>\n%<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
GAAP Net Income Per Share \u2013 Diluted<\/td>\n$<\/td>\n0.50<\/td>\n$<\/td>\n0.45<\/td>\n11.1<\/td>\n%<\/td>\n<\/tr>\n
Non-GAAP Net Income Per Share \u2013 Diluted*<\/td>\n$<\/td>\n0.79<\/td>\n$<\/td>\n0.68<\/td>\n16.2<\/td>\n%<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n As of March 31, 2026 and December 31, 2025<\/strong>
\n
(In thousands)<\/em>
Cash and Cash Equivalents<\/td>\n		\n

$<\/td>\n

\n

755,859<\/td>\n

\n

$<\/td>\n

\n

709,171<\/td>\n

\n

6.6<\/td>\n

\n

%<\/td>\n<\/tr>\n<\/table>\n

_________________________________<\/p>\n

\n *Statements made in this press release include non-GAAP financial measures. Such information is provided as additional information and not as an alternative to Catalyst’s financial statements presented in accordance with U.S.\u00a0generally accepted accounting principles (“GAAP”). These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst’s current financial performance. Catalyst believes that the non-GAAP financial measures presented in this press release provide investors and prospective investors with an alternative method for assessing Catalyst’s operating results in a manner that Catalyst believes is focused on the performance of ongoing operations and provides a more consistent basis for comparison between periods. Non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP accounting. Further, non-GAAP measures of net income used by Catalyst may be different from and not directly comparable to similarly titled measures used by other companies. <\/em><\/sup>\n <\/p>\n

\n First Quarter 2026 Financial Highlights<\/strong>
\n
The Company delivered strong first quarter 2026 results.<\/p>\n